Follow us on LinkedIn
Because we care!
Of course, our QM system is certified according to IVDR!
Dies Freeze-drying service:
Due to increased demand, we have decided to offer our considerable experience in the lyophilisation of LAMP assays as a service to you.
For more information, please read here....
New Innovative Molecular Technology
Combination “LAMP + CRISPR” as CE-IVD
First Product: eazySNP C. auris FKS1 S639 (CE-IVD)
With the first application of the eazySNP technology, AmplexDiagnostics targets one of the world's most significant multidrug-resistant yeast pathogens: Candidozyma auris. “eazySNP C. auris FKS1 S639” is the first CE-IVD diagnostic test of its kind and enables the highly specific detection of clinically relevant mutations in the FKS1 gene associated with echinocandin resistance. As echinocandins currently represent the first-line treatment option for C. auris infections, the rapid identification of resistance-associated variants is of considerable clinical importance. The assay is performed directly from a yeast colony on the AmplexDiagnostics eazyMini platform and delivers results within just 45 minutes. The eazySNP technology therefore provides, for the first time, a rapid and targeted molecular solution for the detection of this important resistance marker.
We did it again.
Another eazyplex® kit is now available!
And with the new eazyplex® hv-K. pneumoniae, we are once again bringing a highly topical test to the market on a subject that is still underestimated in many hospitals.
“Candida auris poses a risk to patients in healthcare settings across Europe due to its propensity to cause outbreaks and its resistance to antifungal drugs. Difficulties in laboratory identification and a lack of awareness of this Candida species can delay early detection and reduce the potential increase for a horizontal transfer."
European Center for Disease Prevention and Control. Candida auris in healthcare settings - Europe - first update, 23 April 2018. Stockholm: ECDC; 2018
When every minute counts - eazyplex® BloodScreen! Help for therapy decision - in 20 minutes!
Early diagnosis and prompt, appropriate clinical therapy for sepsis are critical to increasing the chances of survival. Antibiotic resistance is a key factor determining clinical responsiveness to treatment and rapid disease progression in sepsis and septic shock.
STDs travel overnight, Stop it now!
Our new eazyplex® STD complete is now CE IVD certified. You can now detect sexually transmitted pathogens in just 25 minutes - straight from the swab sample.
This is why you should use the eazyplex® system!
